Panel, Conference Presentation
The Future of Health: A New World of Collaboration
- Long-term biomedical support aims to reduce redundancy and sharing costs while preserving competitive spirit, with the collaboration model projected to serve as a template for successful industry, academic, and intra-academic partnerships.
- Antibiotic stewardship efforts anticipate global collaboration to end routine agricultural antibiotic use and prevent resistance loss, driven by joint responsibility among clinicians, patients, and farmers rather than blame-shifting.
- Linking biomedical ecosystem segments is expected to accelerate the understanding of therapeutics and biomarkers for diabetes, Alzheimer's, rheumatoid arthritis, lupus, Parkinson's, and cancer immunotherapy.
- Future accessibility of genomic and precision medicine requires integrating reimbursement strategies with clinical advances, alongside increased human capital productivity projected to raise life expectancy in South Asia and Southeast Asia by 80% over slightly more than two generations.
- Corporations are expected to assume greater leadership in prevention and wellness to lower long-term costs through early diagnosis, with private business innovation anticipated to outpace government speed in setting standards.
- Significant reductions in smoking-related disease expenses are forecasted if smoking is prohibited on company properties, while public health students are increasingly gravitating toward leadership tracks.
- Educational approaches for public health must combine internships, career-building opportunities, and mentoring, as the NIH is expected to shift focus toward prevention to avoid illness.
- U.S. obesity rates will require diverse strategies including basic metabolism research and social contributions, with a prediction that maintaining 1991 weight levels could increase the U.S. economy by $1.5 to $2 trillion.
- Obesity has tripled globally since 1975, affecting 1.9 billion people, and is identified as a risk factor for 40% of U.S. cancers (55% in men, 24% in women), contributing to a life expectancy downturn in the U.S. linked to obesity, opioids, alcohol, and suicide.
- The "All of Us" precision medicine program plans to launch in the spring following beta testing to enroll one million Americans in a longitudinal study, funded for the next 10 years by the 21st Century Cures Bill, with the dataset serving as a discovery engine while protecting privacy.
- 10% to 12% of companies formed today focus on early detection and diagnosis, which is viewed as the primary hope for cost reduction, while metabolic disease is identified as a critical investment area due to economic and social consequences.
- The opioid epidemic requires a national prevention and treatment focus, with 80% of addicted individuals starting on prescription opioids, current addiction rates at two million people, and 10% of newborn ICU infants addicted at birth due to maternal addiction.
- A focused effort on medication-assisted treatments, overdose interventions, and non-addictive pain medicines involves 33 companies working with the NIH and FDA, based on the belief that treatment programs without medication assistance have relapse rates approaching 100%.
- Government support for biomedical research is expected to decline by approximately 20% in purchasing power compared to 2003, requiring correction to prevent the loss of future living standards.
- Chronic disease prevention is described as unachievable by the healthcare system alone, requiring a collective focus, while environmental structures like floating staircases are seen as capable of impacting community health.
- An explosion in costs related to chronic disease is expected to divert researchers and funds away from solving life-threatening diseases, necessitating resources for scientific enterprises to make fundamental discoveries.